Yiannis Kiachopoulos
CEO
Causaly
10/10Traction
Causaly is a generative AI platform that automates knowledge extraction from vast biomedical literature, enabling researchers to identify validated targets and novel biomarkers with high precision. By reducing research time from months to minutes, it enhances productivity by up to 90%, allowing scientists to focus on innovative drug discovery.
- Artificial Intelligence
- Data & Analytics
- Biotechnology
- Software Only
Updated 5 months ago
Funding
Raised to date
$90.7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
EbrdvcipNo round attributed
- ebrdvcip.com (opens in a new tab)investor website
Emerge CapitalNo round attributed
- emergecapital.vc (opens in a new tab)investor website
Marathon Venture CapitalNo round attributed
- marathon.vc (opens in a new tab)investor website
PentechNo round attributed
- pentech.vc (opens in a new tab)investor website
PentechvcNo round attributed
- pentechvc.com (opens in a new tab)investor website
Funding rounds are not available yet.
Founders
Product
Problem
Biomedical researchers face the challenge of efficiently extracting relevant knowledge from the exponentially growing volume of scientific literature. Traditional research methods are time-consuming, can introduce bias, and may overlook critical connections between data points, hindering the pace of drug discovery and biomarker identification.
Solution
Causaly offers a generative AI platform designed to automate knowledge extraction and analysis from vast amounts of biomedical literature, accelerating research insights for scientists. The platform employs a human-centric AI approach to sift through data, reduce bias, and identify validated targets and novel biomarkers with high precision. By significantly reducing research time, Causaly enables researchers to focus on innovative drug discovery, explore new therapeutic areas, and understand disease mechanisms more effectively. The platform helps manage the increasing volume of biomedical data, separating signal from noise to boost research productivity.
Target Audience
The primary users are biomedical research and development teams, including translational research scientists, biomarker identification specialists, and principal scientists in pharmaceutical and biotechnology companies.
Features
- Generative AI-powered knowledge extraction from biomedical literature
- High-precision search capabilities to navigate scientific data efficiently
- Identification of validated targets and novel biomarkers
- Bias reduction in data analysis
- Delta Analysis feature for comparing therapeutic applications across diseases
- Multi-hop module for generating insights and hypotheses